NO924925L - Bradykinin-antagonister for behandling av akutt betennelse i bukspyttkjertelen - Google Patents

Bradykinin-antagonister for behandling av akutt betennelse i bukspyttkjertelen

Info

Publication number
NO924925L
NO924925L NO92924925A NO924925A NO924925L NO 924925 L NO924925 L NO 924925L NO 92924925 A NO92924925 A NO 92924925A NO 924925 A NO924925 A NO 924925A NO 924925 L NO924925 L NO 924925L
Authority
NO
Norway
Prior art keywords
hyp
gly
pro
substituted
treatment
Prior art date
Application number
NO92924925A
Other languages
English (en)
Other versions
NO924925D0 (no
Inventor
Thomas Griesbacher
Fred Lembeck
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO924925D0 publication Critical patent/NO924925D0/no
Publication of NO924925L publication Critical patent/NO924925L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043Kallidins; Bradykinins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/18Kallidins; Bradykinins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anvendelse av bradykinln-antagonlster med formel Ri-A-B-C-E-F-G-J-K-R2 hvor R1 betyr hydrogen, C1-C4-alkanoyl som kan bli substituert med merkapto, hydroksyfenyl (4-benzoyl)- fenoksy eller betyr (4-benzoyl )benzoyl-Lys, A betyr A- Arg eller D-Lys eller betyr en direktebindlng; B betyr Arg som kan bli substituert med N02 eller toluol-4- sulfonyl eller betyr Lys som kan være substituert med toluol 4-sulfonyl eller CO-NH-C6H5, eller betyr en direkte binding; C betyr Hyp-Pro-Gly, Pro-Hyp-Gly, Pro- Pro-Gly eller dehydroPro-Hyp-Gly; E betyr Thi, Phe, Leu eller Cha; F betyr Ser eller Cys; G betyr D-Tic, D-Phe eller D-Hyp substituert med C1-C4-alkoksy; J betyr Tie, Aoc eller Ole; K betyr Arg eller Ahx eller betyr en direkte binding; R2 er hydroksy eller amino; og fysiologisk tolererbare salter derav for behandling av akutt betennelse i bukspyttkjertelen er beskrevet. FArmasøytiske midler inneholdende disse og anvendelse derav for fremstilling av hensiktsmessige farmasøytiske forbindelser er også beskrevet.
NO92924925A 1991-12-21 1992-12-18 Bradykinin-antagonister for behandling av akutt betennelse i bukspyttkjertelen NO924925L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91122055 1991-12-21

Publications (2)

Publication Number Publication Date
NO924925D0 NO924925D0 (no) 1992-12-18
NO924925L true NO924925L (no) 1993-06-22

Family

ID=8207466

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924925A NO924925L (no) 1991-12-21 1992-12-18 Bradykinin-antagonister for behandling av akutt betennelse i bukspyttkjertelen

Country Status (27)

Country Link
US (1) US5670619A (no)
EP (1) EP0548825B1 (no)
JP (1) JP3588472B2 (no)
KR (1) KR930012034A (no)
CN (1) CN1073603A (no)
AT (1) ATE152733T1 (no)
AU (1) AU662188B2 (no)
BG (1) BG97168A (no)
BR (1) BR9205062A (no)
CA (1) CA2085781C (no)
CY (1) CY2116B1 (no)
CZ (1) CZ375692A3 (no)
DE (1) DE69219574T2 (no)
DK (1) DK0548825T3 (no)
ES (1) ES2101017T3 (no)
FI (1) FI925782A (no)
GR (1) GR3024179T3 (no)
HU (1) HU214056B (no)
IL (1) IL104163A0 (no)
MA (1) MA22743A1 (no)
MX (1) MX9207440A (no)
NO (1) NO924925L (no)
PL (1) PL297044A1 (no)
SI (1) SI9200406A (no)
TW (1) TW199863B (no)
YU (1) YU108192A (no)
ZA (1) ZA929829B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105172B1 (en) 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
US20040248809A1 (en) * 2003-02-07 2004-12-09 Aventis Pharma Deutschland Gmbh Use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis
RU2425669C1 (ru) * 2010-04-13 2011-08-10 Общество С Ограниченной Ответственностью "Гамаветфарм" Средство для профилактики и лечения острого и хронического панкреатита

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0009010B1 (en) * 1978-07-18 1983-03-02 Kabi AB Bradykinin inhibiting tripeptide derivatives, process for their preparation and pharmaceutical preparations containing them
US4693993A (en) * 1985-06-13 1987-09-15 Stewart John M Bradykinin antagonist peptides
US4801613A (en) * 1985-06-13 1989-01-31 Nova Technology Limited Partnership Bradykinin antagonist peptides
US4923963A (en) * 1987-09-02 1990-05-08 Nova Technology Limited Partnership Bradykinin antagonist peptides
US5162497A (en) * 1987-09-24 1992-11-10 The Administrators Of The Tulane Educational Fund Bradykinin analogs with non-peptide bond
DE4013270A1 (de) * 1990-04-26 1991-10-31 Hoechst Ag Peptide mit bradykinin-antagonistischer wirkung
DE3926822A1 (de) * 1989-08-14 1991-02-21 Hoechst Ag Peptide mit bradykinin-antagonistischer wirkung
IE63490B1 (en) * 1988-11-24 1995-05-03 Hoechst Ag Peptides having bradykinin antagonist action
DE69012142D1 (de) * 1989-12-08 1994-10-06 Univ Boston Acylierte bradykininantagonisten und deren verwendung.
EP0451791A2 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft Langwirksame Liposomenpräparate von Peptidarzneistoffen und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
ES2101017T3 (es) 1997-07-01
ZA929829B (en) 1994-02-16
JPH05255107A (ja) 1993-10-05
AU662188B2 (en) 1995-08-24
FI925782A0 (fi) 1992-12-18
DE69219574D1 (de) 1997-06-12
BR9205062A (pt) 1993-09-28
MX9207440A (es) 1993-07-01
FI925782A (fi) 1993-06-22
JP3588472B2 (ja) 2004-11-10
EP0548825A1 (en) 1993-06-30
NO924925D0 (no) 1992-12-18
DK0548825T3 (da) 1997-11-03
TW199863B (no) 1993-02-11
BG97168A (bg) 1993-12-24
CA2085781A1 (en) 1993-06-22
DE69219574T2 (de) 1997-11-13
PL297044A1 (en) 1993-09-06
CN1073603A (zh) 1993-06-30
SI9200406A (en) 1993-06-30
HU214056B (en) 1997-12-29
IL104163A0 (en) 1993-05-13
ATE152733T1 (de) 1997-05-15
YU108192A (sh) 1995-12-04
MA22743A1 (fr) 1993-07-01
GR3024179T3 (en) 1997-10-31
CA2085781C (en) 2003-09-23
EP0548825B1 (en) 1997-05-07
US5670619A (en) 1997-09-23
CY2116B1 (en) 2002-04-26
CZ375692A3 (en) 1993-12-15
HU9204074D0 (en) 1993-04-28
KR930012034A (ko) 1993-07-20
HUT63336A (en) 1993-08-30
AU3021292A (en) 1993-06-24

Similar Documents

Publication Publication Date Title
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
PT2311432E (pt) Polipeptídeos de domínio kunitz modificado e sua utilização para a redução de isquemia ou aparecimento de uma resposta inflamatória sistémica associada a um procedimento cirúrgico
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
DK0946191T3 (da) Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme
TR200103337T2 (tr) Protez inhibit”rleri olarak yeni bileçikler ve bileçimler
DK1179014T3 (da) Derivater af Z-domænet fra staphylococcalt protein A (SPA), som interagerer med mindst ét domæne fra human faktor VIII
NO20063026L (no) Antistoffer
ATE297219T1 (de) Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
NO942553D0 (no) Ny humanproteaseinhibitor av Kunitz-type og varianter derav
DE69221486D1 (de) Bombesinanaloge
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
ATE198603T1 (de) Bivalente thrombininhibitore
DK0526313T3 (da) Nye ureaderivater, deres fremstilling og terapeutiske anvendelse
NO924925L (no) Bradykinin-antagonister for behandling av akutt betennelse i bukspyttkjertelen
HUP0301523A2 (hu) VEGF-peptidek és alkalmazásuk angiogenezis gátlására
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
MX9205978A (es) Nuevas proteinas inhibidoras de trombina de garrapatas.
RU92016227A (ru) Лекарственная композиция, включающая антагонисты брадикинина, используемая в лечении острого панкреатита, способ ее получения и использование
TH13940A (th) เบรดีไคนิน-แอนตาโกนิส สำหรับใช้บำบัดตับอ่อนอักเสบเฉียบพลัน
TH13940EX (th) เบรดีไคนิน-แอนตาโกนิส สำหรับใช้บำบัดตับอ่อนอักเสบเฉียบพลัน
DE50013908D1 (de) Zytotoxisches t-zellepitop des papillomavirus l1-proteins und seine verwendung in diagnostik und therapie
NO20082810L (no) Vaksine, og anvendelse av samme
ECSP972344A (es) Proteinas antiobesidad